Machine learning offers great promise for fast and accurate binding affinity predictions. However, current models lack robust evaluation and fail on tasks encountered in (hit-to-) lead optimisation, such as ranking the binding affinity of a congeneric series of ligands, thereby limiting their application in drug discovery. Here, we address these issues by first introducing a novel attention-based graph neural network model called AEV-PLIG (atomic environment vector–protein ligand interaction graph). Second, we introduce a new and more realistic out-of-distribution test set called the OOD Test. We benchmark our model on this set, CASF-2016, and a test set used for free energy perturbation (FEP) calculations, that not only highlights the competitive performance of AEV-PLIG, but provides a realistic assessment of machine learning models with rigorous physics-based approaches. Moreover, we demonstrate how leveraging augmented data (generated using template-based modelling or molecular docking) can significantly improve binding affinity prediction correlation and ranking on the FEP benchmark (weighted mean PCC and Kendall’s τ increases from 0.41 and 0.26 to 0.59 and 0.42). These strategies together are closing the performance gap with FEP calculations (FEP+ achieves weighted mean PCC and Kendall’s τ of 0.68 and 0.49 on the FEP benchmark) while being ~400,000 times faster.
Controlling the formation and growth of ice is essential to successfully cryopreserve cells, tissues and biologics. Current efforts to identify materials capable of modulating ice growth are guided by iterative changes and human intuition, with a major focus on proteins and polymers. With limited data, the discovery pipeline is constrained by a poor understanding of the mechanisms and the underlying structure-activity relationships. In this work, this barrier is overcome by constructing machine learning models capable of predicting the ice recrystallisation inhibition activity of small molecules. We generate a new dataset via experimental measurements of ice growth, then harness predictive models combining state-of-the-art descriptors with domain-specific features derived from molecular simulations. The models accurately identify potent small molecule ice recrystallisation inhibitors within a commercial compound library. Identified hits can also mitigate cellular damage during transient warming events in cryopreserved red blood cells, demonstrating how data-driven approaches can be used to discover innovative cryoprotectants and enable next-generation cryopreservation solutions for the cold chain.
Ice recrystallisation inhibition (IRI) is typically associated with ice binding proteins, but polymers and other mimetics are emerging. Here we identify phenylalanine as a minimalistic, yet potent, small-molecule IRI capable of inhibiting ice growth at just 1 mg mL−1. Facial amphiphilicity is shown to be a crucial structural feature, with para-substituents enhancing (hydrophobic) or decreasing (hydrophilic) IRI activity. Both amino and acid groups were found to be essential. Solution-phase self-assembly of Phenylalanine was not observed, but the role of self-assembly at the ice/water interface could not be ruled out as a contributing factor.
Machine learning offers a promising approach for fast and accurate binding affin- ity predictions. However, current models often fail to generalise beyond their training data and are not robustly evaluated on a diverse range of benchmarks, limiting their application in drug discovery projects. In this work, we address these issues by intro- ducing a novel graph neural network model called AEV-PLIG (Atomic Environment Vector - Protein Ligand Interaction Graph), which encodes protein-ligand interactions via atomic environment vectors to improve generalisation. We evaluate our model on improved benchmarks, including our new out-of-distribution test set we call OOD Test, and two alternative benchmark systems used for free energy perturbation (FEP) calculations, and highlight competitive performance of AEV-PLIG across the board. Moreover, we demonstrate how augmented data can be leveraged to enhance predic- tion accuracy, and how enriching the training data with three complexes from a con- generic series of ligands binding to a target of interest improves performance further. Altogether, we show that these strategies improve the applicability of machine learn- ing scoring functions and enable state-of-the-art performance nearing the accuracy of physics-based simulation methods—but at a fraction of their computational cost. This practical approach extends the predictive capabilities of machine learning for molecular discovery, paving the way for its broader use in computer-aided drug design.